Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.69 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | AGER | Q15109 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10898466 | 0.91 | LMNA (0.68) | TDP1ALDH1A1MAPK8KMT2APDE10A | |
| SCHEMBL8730078 | 0.91 | TDP1 (0.65) | TDP1ALDH1A1MAPK8KMT2APDE10A | |
| SCHEMBL11810048 | 0.88 | PDE10A (0.60) | TDP1ALDH1A1MAPK8KMT2APDE10A | |
| SCHEMBL2779361 | 0.87 | KMT2A (0.65) | TDP1ALDH1A1MAPK8KMT2APDE10A | |
| SCHEMBL1797073 | 0.87 | TDP1 (0.56) | TDP1ALDH1A1MAPK8KMT2APDE10A | |
| SCHEMBL2781160 | 0.87 | GAA (0.67) | TDP1ALDH1A1MAPK8KMT2APDE10A | |
| SCHEMBL5216488 | 0.87 | TDP1 (0.56) | TDP1ALDH1A1MAPK8KMT2APDE10A | |
| SCHEMBL6457226 | 0.87 | TDP1 (0.64) | TDP1ALDH1A1MAPK8PDE10ARAB9A | |
| SCHEMBL2779334 | 0.87 | RAB9A (0.76) | TDP1ALDH1A1MAPK8KMT2APDE10A | |
| SCHEMBL13692388 | 0.86 | TDP1 (0.72) | TDP1ALDH1A1MAPK8KMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 198 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117510338-A | Natural naphthoquinone derivative and preparation method and application thereof | 贵州大学 | 2024-02-06 | — | — | CN | claimed |
| CN-114849638-A | Reaction kettle for producing diflufenican technical and preparation process thereof | 池州飞昊达化工有限公司 | 2022-08-05 | — | — | CN | claimed |
| US-7642344-B2 | Methods and compositions for determining the sequence of nucleic acid molecules | OPERON BIOTECHNOLOGIES, INC. (US) | 2010-01-05 | — | — | US | claimed |
| EP-0992511-B1 | Methods and compositions for determining the sequence of nucleic acid molecules | OPERON BIOTECHNOLOGIES INC (US) | 2009-03-11 | — | — | EP | claimed |
| US-20080009613-A1 | Methods and compositions for determining the sequence of nucleic acid molecules | OPERON BIOTECHNOLOGIES, INC. (US) | 2008-01-10 | — | — | US | claimed |
| US-7247434-B2 | Methods and compositions for determining the sequence of nucleic acid molecules | OPERON BIOTECHNOLOGIES, INC. (US) | 2007-07-24 | — | — | US | claimed |
| EP-0868535-B9 | METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES | QIAGEN GENOMICS INC (US) | 2007-05-09 | — | — | EP | claimed |
| EP-1392219-A4 | SUBSTITUTED N'-(ARYLCARBONYL)-BENZHYDRAZIDES, N'-(ARYLCARBONYL)-BENZYLIDENE-HYDRAZIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOTOSIS AND THE USE THEREOF | CYTOVIA INC (US) | 2007-01-24 | — | — | EP | claimed |
| EP-0868535-B2 | METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES | QIAGEN GENOMICS INC (US) | 2006-01-04 | — | — | EP | claimed |
| US-20040186078-A1 | Substituted N'-(arylcarbonyl)-benzhydrazides, N'-(arylcarbonyl)-benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2004-09-23 | — | — | US | claimed |
| CN-1212019-A | Methods and compositions for detecting ligand pair binding using non-fluorescent labels | RAPIGENE INC (US) | 1999-03-24 | — | — | CN | claimed |
| CN-1212021-A | Method and compositions for determining sequence of nucleic acid molecules | RAPIGENE INC (US) | 1999-03-24 | — | — | CN | claimed |
| WO-1999005319-A2 | METHODS AND COMPOUNDS FOR ANALYZING NUCLEIC ACIDS BY MASS SPECTROMETRY | RAPIGENE, INC. (US) | 1999-02-04 | — | — | WO | claimed |
| EP-0868535-A2 | METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES | Rapigene, Inc. (US) | 1998-10-07 | — | — | EP | claimed |
| EP-0850320-A2 | METHODS AND COMPOSITIONS FOR DETECTING BINDING OF LIGAND PAIR USING NON-FLUORESCENT LABEL | DARWIN MOLECULAR CORPORATION (US) | 1998-07-01 | — | — | EP | claimed |
| WO-1997027331-A9 | METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES | — | 1997-10-09 | — | — | WO | claimed |
| WO-1997027331-A2 | METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES | RAPIGENE, INC. (US) | 1997-07-31 | — | — | WO | claimed |
| WO-1997027327-A2 | METHODS AND COMPOSITIONS FOR DETECTING BINDING OF LIGAND PAIR USING NON-FLUORESCENT LABEL | RAPIGENE, INC. (US) | 1997-07-31 | — | — | WO | claimed |
| EP-0075607-B1 | 1-AZAXANTHONE FOR USE AS THERAPEUTIC AGENT, PROCESSES FOR ITS PRODUCTION AND PHARMACEUTICAL COMPOSITIONS | LACER, S.A. (ES) | 1985-03-13 | — | — | EP | claimed |
| EP-0075607-A1 | 1-Azaxanthone for use as therapeutic agent, processes for its production and pharmaceutical compositions | LACER, S.A. (ES) | 1983-04-06 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186078-A1 | Substituted N'-(arylcarbonyl)-benzhydrazides, N'-(arylcarbonyl)-benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP2, CASP1, BCL2 | TDP1 2427/4885ALDH1A1 140/4885MAPK8 3786/4885 |
| US-20080009613-A1 | Methods and compositions for determining the sequence of nucleic acid molecules | CPSF6, RNMT, POLM | TDP1 331/4885ALDH1A1 3332/4885MAPK8 3104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.